VanEck Associates
NDRM

VanEck Associates’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

VanEck Associates’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,943
Closed -$192K – 741
2017
Q3 		$192K Buy
4,943
+220
+5% +$8.09K ﹤0.01% 623
2017
Q2 		$141K Buy
4,723
+468
+11% +$12.1K ﹤0.01% 630
2017
Q1 		$113K Hold
4,255
– – ﹤0.01% 745
2016
Q4 		$94K Sell
4,255
-2,118
-33% -$39.6K ﹤0.01% 739
2016
Q3 		$118K Buy
6,373
+23
+0.4% +$399 ﹤0.01% 702
2016
Q2 		$103K Sell
6,350
-568
-8% -$9.57K ﹤0.01% 686
2016
Q1 		$98K Buy
6,918
+39
+0.6% +$527 ﹤0.01% 676
2015
Q4 		$117K Sell
6,879
-279
-4% -$5.43K ﹤0.01% 608
2015
Q3 		$148K Buy
+7,158
New +$147K ﹤0.01% 590

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

VanEck Associates's NDRM Position: Q4 2017 in Review

VanEck Associates sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 4,943 shares — an estimated $192K sold.

VanEck Associates first reported a position in NDRM in Q3 2015 and held it in 9 quarters. The position peaked at $192K in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • VanEck Associates reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • VanEck Associates sold 4,943 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $192K.
  • VanEck Associates first reported a position in NeuroDerm Ltd. Ordinary Shares in Q3 2015 and held it in 9 quarters.
  • VanEck Associates's NeuroDerm Ltd. Ordinary Shares position peaked at $192K in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on VanEck Associates's 13F filing for Q4 2017, filed 12 Feb 2018.